Aclaris Phase 2a zunsemetinib trial for hidradenitis suppurativa fails to meet endpoints

Aclaris Therapeutics, Inc.

Study did not meet primary endpoint of change in inflammatory nodule/abscess count at week 12.
Secondary endpoints including HiSCR-50 also not met; placebo effect higher than in published HS studies.
Zunsemetinib generally well tolerated; most common AEs: dizziness (16.7%), diarrhea (12.5%), headache (12.5%).
No serious adverse events or opportunistic infections observed; PK/PD consistent with prior studies.
CEO notes next data readout from Phase 2b rheumatoid arthritis study is expected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.